Back to Market返回行情

BVS Bioventus Inc.

USHealthcare
$11.94-1.45%OpenMarket Cap: $808.6M

As of 2026-07-09 13:08

Why BVS matters now

Bioventus Inc. (BVS) is a US stock in Healthcare. The latest InvestLog snapshot shows $11.94 with -1.45% on the session and $808.6M in market capitalization; recent performance reads 1-month -18.29% and YTD +17.07%.

The latest financial table shown here is Q1 2026, with revenue of $132.1M, net income of $3.1M, and EPS of $0.04. Investors can compare that operating picture with valuation signals such as P/E 26.85 and FCF yield 17.1%.

The latest indexable market news headline is "Are You Looking for a Top Momentum Pick? Why Bioventus (BVS) is a Great Choice" from Zacks Investment Research.

Additional event context on this page matters because analyst consensus is Buy with a median target of $14.00; recent insider activity includes Beyer Pat filing A-Award. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

26.85

PEG

0.16

P/B

3.10

P/S

1.02

EV/EBITDA

8.00

DCF Value

$-2.59

FCF Yield

17.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

67.8%

Operating Margin

10.6%

Net Margin

4.9%

ROE

16.3%

ROA

4.4%

ROIC

11.8%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$132.1M$3.1M$0.04
Q4 2025$157.9M$14.8M$0.21
FY 2025$568.1M$22.7M$0.33
Q3 2025$138.7M$3.2M$0.05

Analyst Ratings

Consensus

Buy

Target (Consensus)

$14.00

Target (Median)

$14.00

Target Range

$13.00 - $15.00

Strong Buy: 2Buy: 3Hold: 0Sell: 0Strong Sell: 0
Canaccord GenuityBuy
2026-06-16
Barrington ResearchOutperform
2026-05-22
Barrington ResearchOutperform
2026-03-06
Craig-HallumBuy
2026-03-06

Trading Activity

Insider Trades

Beyer Patdirector
Sell2026-06-04
Cowdy Philip G.director
Sell2026-06-04
HAWKINS WILLIAM Adirector
Sell2026-06-04
Ladone Mary Kaydirector
Sell2026-06-04
McMurry-Heath Michelledirector
Sell2026-06-04

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

0.67

Bioventus Inc. is a global medical technology enterprise specializing in the development and market introduction of clinical solutions that activate and bolster the body's inherent regenerative processes. The company's diverse product range is categorized into three primary segments: Firstly, pain management offerings include minimally invasive joint pain injection therapies and advanced peripheral nerve stimulation devices. Secondly, their surgical innovations feature bone graft substitutes engineered to facilitate bone fusion and growth, thereby improving results in spinal and other orthopedic procedures. This segment also comprises ultrasonic instruments employed for precise bone sculpting, tumor excision, and tissue cleansing. Thirdly, restorative therapies encompass an advanced ultrasonic system for fracture repair, along with skin allografts, specialized products for chronic wound management, and sophisticated rehabilitation devices designed to aid in the recovery of leg and hand function. Bioventus's clientele consists of medical professionals across the entire orthopedic spectrum, such as specialists in sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery. These offerings are utilized in various clinical environments, including private clinics, ambulatory surgical centers, and hospital settings. Established in 2011, Bioventus Inc. maintains its corporate headquarters in Durham, North Carolina.